Disease Management Program Did Not Reduce Racial and Ethnic Disparities in Diabetes Care
A 3-year telephone-based disease management program did not reduce racial and ethnic disparities in diabetes care.
A 3-year telephone-based disease management program did not reduce racial and ethnic disparities in diabetes care.
Trends in antihyperglycemic treatment reveal a decrease in glibenclamide and thiazolidinedione and an increase in gliclazide and dipeptidyl peptidase-4 inhibitors.
Of patients who had doctor-ordered blood tests, 33.6% had glycated hemoglobin levels that indicated prediabetes but very few were told of their condition and only 23% began treatment.
Researchers noted a correlation for annual average particulate matter with higher fasting glucose, homeostasis model assessment of insulin resistance, and low-lipoprotein density cholesterol.
Diabetes Control and Complications Trial reports that patients who were taught intensive therapy for type 1 diabetes experienced clinically beneficial effects on cardiovascular outcomes at 30 years.
Renin inhibitor aliskiren may not reduce albuminuria levels enough for cardiovascular and renal risk protection.
Vitamin D treatment had no effect on first- or second-phase insulin secretion compared with placebo.
Fasting glycemia screening for gestational diabetes had a sensitivity of 78.5%, which would allow for glucose loading to be avoided in 63.8% of women.
Increasing glucose levels correlated with gradual worsening of surgical outcomes, including additional hospital stays, increase in infections, and respiratory complications.
Children treated with antipsychotics have an increased cumulative risk and incidence of type 2 diabetes.